ID: ALA53447

Max Phase: Preclinical

Molecular Formula: C7H5FN4O2

Molecular Weight: 196.14

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1n[n+]([O-])c2cc(F)ccc2[n+]1[O-]

Standard InChI:  InChI=1S/C7H5FN4O2/c8-4-1-2-5-6(3-4)12(14)10-7(9)11(5)13/h1-3H,(H2,9,10)

Standard InChI Key:  JVTREGZZEKECKJ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 196.14

Molecular Weight (Monoisotopic): 196.0397

AlogP: -0.78

#Rotatable Bonds: 0

Polar Surface Area: 92.79

Molecular Species: NEUTRAL

HBA: 4

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.14

CX Basic pKa: 2.13

CX LogP: -0.15

CX LogD: -0.15

Aromatic Rings: 2

Heavy Atoms: 14

QED Weighted: 0.44

Np Likeness Score: -0.75

References

1. Hay MP, Gamage SA, Kovacs MS, Pruijn FB, Anderson RF, Patterson AV, Wilson WR, Brown JM, Denny WA..  (2003)  Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.,  46  (1): [PMID:12502371] [10.1021/jm020367+]

2. Cascioferro S, Parrino B, Spanò V, Carbone A, Montalbano A, Barraja P, Diana P, Cirrincione G..  (2017)  An overview on the recent developments of 1,2,4-triazine derivatives as anticancer compounds.,  142  [PMID:28851503] [10.1016/j.ejmech.2017.08.009]

Source

Source(1):

• Scientific Literature